The drugmaker emphasized the full global rights it would acquire to Momenta's lead asset, nipocalimab, which it is developing for several autoantibody-driven diseases and that in certain indications could have peak sales of more than $1 billion.
Expert says that biosimilars' pricing discounts and lower-than-expected patient populations could make the market less attractive for smaller players.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.